Post-Trial Access to ATH434 for Patients With Multiple System Atrophy
ConditionMultiple System Atrophy
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
AgeNot listed
SponsorAlterity Therapeutics
About this trial
This multicenter post-trial access program is designed to provide ATH434 orally BID to eligible patients who completed Phase 2 studies ATH434-201 or ATH434-202, and who may benefit from this treatment according to the evaluation by their treating physicians.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Completed Alterity protocol ATH434-201 or ATH434-202
Expected to benefit from treatment from treatment with ATH434, in the opinion of the treating physician
Disqualifiers
Discontinued prior ATH434 treatment (ATH434-201 or ATH434-202) for any reason
Significant medical or psychiatric condition that may decrease the benefit-risk ratio of participation in this program to an unacceptable level, as per the treating physician's opinion
Trial design
Treatments tested in this trial
ATH434
DrugATH434 tablets
Treatment groups
No treatment groups listed
Trial outcomes
This trial has no outcomes listed.Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov